Opinionated, data-backed coverage across all asset classes

Comparing the 10% yield of XYLD against the total return potential of SPY reveals the structural trade-offs of capped-upside strategies.

InspireMD withdraws 2026 guidance as it pivots to a Q3 2026 FDA approval target for its original CGuard system. Watch for regulatory updates and TCAR outlook.

Norwegian Cruise Line shares are under pressure after a Q1 revenue miss and a 2026 guidance cut. With an Alpha Score of 51, the focus shifts to future execution.